Wang Weiwei, Xu Yuanhong
Department of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Department of Clinical Laboratory, Fuyang People's Hospital, Fuyang Clinical College, Anhui Medical University, Fuyang 236000, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Nov 30;40(11):1639-1644. doi: 10.12122/j.issn.1673-4254.2020.11.16.
To investigate the characteristics of immunophenotypes and expressions of non-myeloid differentiation antigens in acute myeloid leukemia (AML) and their value in diagnosis and prognostic evaluation of AML.
We examined the immunophenotypes of 109 patients with AML using BD FACSCalibur flow cytometry and analyzed the association of the immunophenotypes and expressions of non-myeloid differentiation antigens with the prognosis and complete remission (CR) rate of the patients.
Immunophenotype analysis showed that the positivity rates of the myeloid differentiation antigens of AML cells decreased in the order of CD13, CD117, CD33, MPO and CD15; the positivity rates of CD117, CD13, CD33 and MPO did not differ significantly ( > 0.05) and were all significantly higher than that of CD15 ( < 0.05). The positivity rates of AML cell non-lineage antigens CD34, CD38, HLA-DR, and CD123 did not differ significantly ( > 0.05). The positivity rates of non-myeloid differentiation antigens decreased in the order of CD9, CD200, CD56 and CD7 in AML cells and were all significantly higher than those of CD25, CD19, CD2, CD10, CD4, CyCD79a and CyCD3 ( < 0.05). Among the 109 AML patients, the CR rates of patients positive for CD7, CD34, CD56 and CD25 were significantly lower than those negative for these antigens ( < 0.05); the CR rates were significantly higher in patients positive for MPO and CD19 than in the negative patients ( < 0.05). Among the 15 AML-M2b patients with AML1-ETO positivity, the CR rate following a single treatment course was significantly lower in patients positive for CD56 than in CD56-negative patients, and CD56-positive patients also had a significantly higher relapse rate within 1 year ( < 0.05).
Immunophenotyping and analysis of non-myeloid differentiation antigens can be of great clinical significance for the diagnosis and prognostic evaluation of AML, and serve also as one of the important bases for the diagnosis and treatment of AML.
探讨急性髓系白血病（AML）免疫表型特征及非髓系分化抗原表达情况及其在AML诊断与预后评估中的价值。
采用BD FACSCalibur流式细胞术检测109例AML患者的免疫表型，并分析免疫表型及非髓系分化抗原表达与患者预后及完全缓解（CR）率的相关性。
免疫表型分析显示，AML细胞髓系分化抗原阳性率从高到低依次为CD13、CD117、CD33、MPO和CD15；CD117、CD13、CD33和MPO阳性率差异无统计学意义（>0.05），均显著高于CD15（<0.05）。AML细胞非系别抗原CD34、CD38、HLA-DR和CD123阳性率差异无统计学意义（>0.05）。AML细胞非髓系分化抗原阳性率从高到低依次为CD9、CD200、CD56和CD7，均显著高于CD25、CD19、CD2、CD10、CD4、CyCD79a和CyCD3（<0.05）。109例AML患者中，CD7、CD34、CD56和CD25阳性患者的CR率显著低于阴性患者（<0.05）；MPO和CD19阳性患者的CR率显著高于阴性患者（<0.05）。15例AML1-ETO阳性的AML-M2b患者中，CD56阳性患者单疗程治疗后的CR率显著低于CD56阴性患者，且CD56阳性患者1年内复发率也显著更高（<0.05）。
免疫表型分析及非髓系分化抗原检测对AML的诊断与预后评估具有重要临床意义，也是AML诊断与治疗的重要依据之一。
